APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Infective Ophthalmic

Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals.

Selected research

Market Outlook & Growth Opportunities

Global Anti-Infective Ophthalmic Market Outlook and Growth Opportunities 2026

23 December 2025196 pages

Choose your research edition.

Industry ResearchAnti-Infective Ophthalmic Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Infective Ophthalmic Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Anti-Infective Ophthalmic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Infective Ophthalmic Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Infective Ophthalmic Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals.

Major manufacturers of anti-infective eye drugs include Novartis, Allergan, Valeant Pharmaceuticals, Santen Pharmaceutical, Lupin Pharmaceuticals, Apotex and Akorn.

This report provides an overview of the global Anti-Infective Ophthalmic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Anti-Infective Ophthalmic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Infective Ophthalmic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Infective Ophthalmic market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Infective Ophthalmic Segment by Company

Novartis

Allergan

Valeant Pharmaceuticals

Santen Pharmaceutical

Lupin Pharmaceuticals

Apotex

Akorn

Anti-Infective Ophthalmic Segment by Type

Antibacterial

Antiviral

Antifungal

Anti-Parasitic

Others

Anti-Infective Ophthalmic Segment by Application

Hospital

Clinic

Household

Others

Anti-Infective Ophthalmic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Infective Ophthalmic status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Infective Ophthalmic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Infective Ophthalmic significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Infective Ophthalmic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Infective Ophthalmic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Infective Ophthalmic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Infective Ophthalmic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Infective Ophthalmic market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Infective Ophthalmic industry.

Chapter 3: Detailed analysis of Anti-Infective Ophthalmic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Infective Ophthalmic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Infective Ophthalmic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Infective Ophthalmic Industry Trends Table 2. Anti-Infective Ophthalmic Industry Drivers Table 3. Anti-Infective Ophthalmic Industry Opportunities and Challenges Table 4. Anti-Infective Ophthalmic Industry Restraints Table 5. Global Anti-Infective Ophthalmic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Infective Ophthalmic Revenue Share by Company (2021-2026) Table 7. Global Anti-Infective Ophthalmic Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anti-Infective Ophthalmic Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Infective Ophthalmic Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Anti-Infective Ophthalmic Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Infective Ophthalmic Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Infective Ophthalmic Company, Product Type & Application Table 13. Global Anti-Infective Ophthalmic Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Infective Ophthalmic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antibacterial Table 18. Significant Companies of Antiviral Table 19. Significant Companies of Antifungal Table 20. Significant Companies of Anti-Parasitic Table 21. Significant Companies of Others Table 22. Global Anti-Infective Ophthalmic Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Anti-Infective Ophthalmic Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Anti-Infective Ophthalmic Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Anti-Infective Ophthalmic Sales Volume Share by Type (2021-2026) Table 26. Global Anti-Infective Ophthalmic Sales Volume Share by Type (2027-2032) Table 27. Global Anti-Infective Ophthalmic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Anti-Infective Ophthalmic Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Anti-Infective Ophthalmic Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Anti-Infective Ophthalmic Sales Value Share by Type (2021-2026) Table 31. Global Anti-Infective Ophthalmic Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Household Table 35. Significant Companies of Others Table 36. Global Anti-Infective Ophthalmic Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Anti-Infective Ophthalmic Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Anti-Infective Ophthalmic Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Anti-Infective Ophthalmic Sales Volume Share by Application (2021-2026) Table 40. Global Anti-Infective Ophthalmic Sales Volume Share by Application (2027-2032) Table 41. Global Anti-Infective Ophthalmic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Anti-Infective Ophthalmic Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Anti-Infective Ophthalmic Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Anti-Infective Ophthalmic Sales Value Share by Application (2021-2026) Table 45. Global Anti-Infective Ophthalmic Sales Value Share by Application (2027-2032) Table 46. Global Anti-Infective Ophthalmic Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Anti-Infective Ophthalmic Sales by Region (2021-2026) & (K Units) Table 48. Global Anti-Infective Ophthalmic Sales Market Share by Region (2021-2026) Table 49. Global Anti-Infective Ophthalmic Sales by Region (2027-2032) & (K Units) Table 50. Global Anti-Infective Ophthalmic Sales Market Share by Region (2027-2032) Table 51. Global Anti-Infective Ophthalmic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Anti-Infective Ophthalmic Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Anti-Infective Ophthalmic Sales Value Share by Region (2021-2026) Table 54. Global Anti-Infective Ophthalmic Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Anti-Infective Ophthalmic Sales Value Share by Region (2027-2032) Table 56. Global Anti-Infective Ophthalmic Market Average Price (USD/Unit) by Region (2021-2026) Table 57. Global Anti-Infective Ophthalmic Market Average Price (USD/Unit) by Region (2027-2032) Table 58. Global Anti-Infective Ophthalmic Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Anti-Infective Ophthalmic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Anti-Infective Ophthalmic Sales by Country (2021-2026) & (K Units) Table 61. Global Anti-Infective Ophthalmic Sales Market Share by Country (2021-2026) Table 62. Global Anti-Infective Ophthalmic Sales by Country (2027-2032) & (K Units) Table 63. Global Anti-Infective Ophthalmic Sales Market Share by Country (2027-2032) Table 64. Global Anti-Infective Ophthalmic Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Anti-Infective Ophthalmic Sales Value Market Share by Country (2021-2026) Table 66. Global Anti-Infective Ophthalmic Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Anti-Infective Ophthalmic Sales Value Market Share by Country (2027-2032) Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 71. Novartis Anti-Infective Ophthalmic Product Portfolio Table 72. Novartis Recent Development Table 73. Allergan Company Information Table 74. Allergan Business Overview Table 75. Allergan Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. Allergan Anti-Infective Ophthalmic Product Portfolio Table 77. Allergan Recent Development Table 78. Valeant Pharmaceuticals Company Information Table 79. Valeant Pharmaceuticals Business Overview Table 80. Valeant Pharmaceuticals Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 81. Valeant Pharmaceuticals Anti-Infective Ophthalmic Product Portfolio Table 82. Valeant Pharmaceuticals Recent Development Table 83. Santen Pharmaceutical Company Information Table 84. Santen Pharmaceutical Business Overview Table 85. Santen Pharmaceutical Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 86. Santen Pharmaceutical Anti-Infective Ophthalmic Product Portfolio Table 87. Santen Pharmaceutical Recent Development Table 88. Lupin Pharmaceuticals Company Information Table 89. Lupin Pharmaceuticals Business Overview Table 90. Lupin Pharmaceuticals Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Lupin Pharmaceuticals Anti-Infective Ophthalmic Product Portfolio Table 92. Lupin Pharmaceuticals Recent Development Table 93. Apotex Company Information Table 94. Apotex Business Overview Table 95. Apotex Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Apotex Anti-Infective Ophthalmic Product Portfolio Table 97. Apotex Recent Development Table 98. Akorn Company Information Table 99. Akorn Business Overview Table 100. Akorn Anti-Infective Ophthalmic Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. Akorn Anti-Infective Ophthalmic Product Portfolio Table 102. Akorn Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Anti-Infective Ophthalmic Distributors List Table 106. Anti-Infective Ophthalmic Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Anti-Infective Ophthalmic Product Image Figure 2. Global Anti-Infective Ophthalmic Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Infective Ophthalmic Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Infective Ophthalmic Sales (2021-2032) & (K Units) Figure 5. Global Anti-Infective Ophthalmic Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Anti-Infective Ophthalmic Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antibacterial Image Figure 10. Antiviral Image Figure 11. Antifungal Image Figure 12. Anti-Parasitic Image Figure 13. Others Image Figure 14. Global Anti-Infective Ophthalmic Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Anti-Infective Ophthalmic Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-Infective Ophthalmic Sales Volume Share by Type (2021-2032) Figure 17. Global Anti-Infective Ophthalmic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Anti-Infective Ophthalmic Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Anti-Infective Ophthalmic Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Household Image Figure 23. Others Image Figure 24. Global Anti-Infective Ophthalmic Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Anti-Infective Ophthalmic Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Anti-Infective Ophthalmic Sales Volume Share by Application (2021-2032) Figure 27. Global Anti-Infective Ophthalmic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Anti-Infective Ophthalmic Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Anti-Infective Ophthalmic Sales Value Share by Application (2021-2032) Figure 30. Global Anti-Infective Ophthalmic Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Anti-Infective Ophthalmic Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Anti-Infective Ophthalmic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Anti-Infective Ophthalmic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Anti-Infective Ophthalmic Sales Value (2021-2032) & (US$ Million) Figure 35. North America Anti-Infective Ophthalmic Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Anti-Infective Ophthalmic Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Anti-Infective Ophthalmic Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Anti-Infective Ophthalmic Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Anti-Infective Ophthalmic Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Anti-Infective Ophthalmic Sales Value (2021-2032) & (US$ Million) Figure 41. South America Anti-Infective Ophthalmic Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Anti-Infective Ophthalmic Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Anti-Infective Ophthalmic Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Anti-Infective Ophthalmic Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Anti-Infective Ophthalmic Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Antibacterial
  • Antiviral
  • Antifungal
  • Anti-Parasitic
  • Others
Applications
  • Hospital
  • Clinic
  • Household
  • Others
Companies covered
  • Novartis
  • Allergan
  • Valeant Pharmaceuticals
  • Santen Pharmaceutical
  • Lupin Pharmaceuticals
  • Apotex
  • Akorn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Infective Ophthalmic Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Infective Ophthalmic Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Infective Ophthalmic Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Infective Ophthalmic Market Dynamics
  1. 2.1 Anti-Infective Ophthalmic Industry Trends
  2. 2.2 Anti-Infective Ophthalmic Industry Drivers
  3. 2.3 Anti-Infective Ophthalmic Industry Opportunities and Challenges
  4. 2.4 Anti-Infective Ophthalmic Industry Restraints
3 Anti-Infective Ophthalmic Market by Company
  1. 3.1 Global Anti-Infective Ophthalmic Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Infective Ophthalmic Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Infective Ophthalmic Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Infective Ophthalmic Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Infective Ophthalmic Company Ranking (2024-2026)
  6. 3.6 Global Anti-Infective Ophthalmic Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Infective Ophthalmic Company Product Type and Application
  8. 3.8 Global Anti-Infective Ophthalmic Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Infective Ophthalmic Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Infective Ophthalmic Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Infective Ophthalmic Market by Type
  1. 4.1 Anti-Infective Ophthalmic Type Introduction
  2. 4.1.1 Antibacterial
  3. 4.1.2 Antiviral
  4. 4.1.3 Antifungal
  5. 4.1.4 Anti-Parasitic
  6. 4.1.5 Others
  7. 4.2 Global Anti-Infective Ophthalmic Sales Volume by Type
  8. 4.2.1 Global Anti-Infective Ophthalmic Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Anti-Infective Ophthalmic Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Anti-Infective Ophthalmic Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Anti-Infective Ophthalmic Sales Value by Type
  12. 4.3.1 Global Anti-Infective Ophthalmic Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Anti-Infective Ophthalmic Sales Value by Type (2021-2032)
  14. 4.3.3 Global Anti-Infective Ophthalmic Sales Value Share by Type (2021-2032)
5 Anti-Infective Ophthalmic Market by Application
  1. 5.1 Anti-Infective Ophthalmic Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Household
  5. 5.1.4 Others
  6. 5.2 Global Anti-Infective Ophthalmic Sales Volume by Application
  7. 5.2.1 Global Anti-Infective Ophthalmic Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anti-Infective Ophthalmic Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Anti-Infective Ophthalmic Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Anti-Infective Ophthalmic Sales Value by Application
  11. 5.3.1 Global Anti-Infective Ophthalmic Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anti-Infective Ophthalmic Sales Value by Application (2021-2032)
  13. 5.3.3 Global Anti-Infective Ophthalmic Sales Value Share by Application (2021-2032)
6 Anti-Infective Ophthalmic Regional Sales and Value Analysis
  1. 6.1 Global Anti-Infective Ophthalmic Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Infective Ophthalmic Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Infective Ophthalmic Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Infective Ophthalmic Sales by Region (2027-2032)
  5. 6.3 Global Anti-Infective Ophthalmic Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Infective Ophthalmic Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Infective Ophthalmic Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Infective Ophthalmic Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Infective Ophthalmic Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Infective Ophthalmic Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Infective Ophthalmic Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Infective Ophthalmic Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Infective Ophthalmic Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Infective Ophthalmic Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Infective Ophthalmic Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Infective Ophthalmic Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Infective Ophthalmic Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Infective Ophthalmic Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Infective Ophthalmic Sales Value Share by Country, 2025 VS 2032
7 Anti-Infective Ophthalmic Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Infective Ophthalmic Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Infective Ophthalmic Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Infective Ophthalmic Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Infective Ophthalmic Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Infective Ophthalmic Sales by Country (2027-2032)
  6. 7.4 Global Anti-Infective Ophthalmic Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Infective Ophthalmic Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Infective Ophthalmic Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Infective Ophthalmic Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Infective Ophthalmic Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Infective Ophthalmic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Anti-Infective Ophthalmic Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Anti-Infective Ophthalmic Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 Valeant Pharmaceuticals
  14. 8.3.1 Valeant Pharmaceuticals Company Information
  15. 8.3.2 Valeant Pharmaceuticals Business Overview
  16. 8.3.3 Valeant Pharmaceuticals Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Valeant Pharmaceuticals Anti-Infective Ophthalmic Product Portfolio
  18. 8.3.5 Valeant Pharmaceuticals Recent Developments
  19. 8.4 Santen Pharmaceutical
  20. 8.4.1 Santen Pharmaceutical Company Information
  21. 8.4.2 Santen Pharmaceutical Business Overview
  22. 8.4.3 Santen Pharmaceutical Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Santen Pharmaceutical Anti-Infective Ophthalmic Product Portfolio
  24. 8.4.5 Santen Pharmaceutical Recent Developments
  25. 8.5 Lupin Pharmaceuticals
  26. 8.5.1 Lupin Pharmaceuticals Company Information
  27. 8.5.2 Lupin Pharmaceuticals Business Overview
  28. 8.5.3 Lupin Pharmaceuticals Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lupin Pharmaceuticals Anti-Infective Ophthalmic Product Portfolio
  30. 8.5.5 Lupin Pharmaceuticals Recent Developments
  31. 8.6 Apotex
  32. 8.6.1 Apotex Company Information
  33. 8.6.2 Apotex Business Overview
  34. 8.6.3 Apotex Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Apotex Anti-Infective Ophthalmic Product Portfolio
  36. 8.6.5 Apotex Recent Developments
  37. 8.7 Akorn
  38. 8.7.1 Akorn Company Information
  39. 8.7.2 Akorn Business Overview
  40. 8.7.3 Akorn Anti-Infective Ophthalmic Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Akorn Anti-Infective Ophthalmic Product Portfolio
  42. 8.7.5 Akorn Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Infective Ophthalmic Value Chain Analysis
  2. 9.1.1 Anti-Infective Ophthalmic Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Infective Ophthalmic Sales Mode & Process
  6. 9.2 Anti-Infective Ophthalmic Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Infective Ophthalmic Distributors
  9. 9.2.3 Anti-Infective Ophthalmic Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst